Market research
CWBR CohBar Inc
OTCMKTS USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 1M
- P/E ratio
- Not available
- Analyst target
- 18
- Dividend yield
- Not available
- Beta
- 1.38
Profile
Company facts
- Exchange
- OTCMKTS
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US19249J1097
- Market cap
- 1M
- P/E ratio
- Not available
- Analyst target
- 18
- Dividend yield
- Not available
- Beta
- 1.38
About
About CohBar Inc
CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CWBR discussion.
5 years, 4 months ago
CohBar, Inc is currently in a long term downtrend where the price is trading 5.8% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
CohBar, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 337.6% to $-16M since the same quarter in the previous year.
Finally, its free cash flow fell by 8.6% to $-2M since the same quarter in the previous year.
Based on the above factors, CohBar, Inc gets an overall score of 1/5.